Ding Ling, Weygant Nathaniel, Ding Chenhuan, Lai Yi, Li He
Traditional Chinese Medicine Department, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Crit Rev Oncol Hematol. 2023 Nov;191:104118. doi: 10.1016/j.critrevonc.2023.104118. Epub 2023 Sep 2.
DCLK1, a tuft cell marker, is widely expressed in various tumors. Its high expression levels are closely linked to malignant tumor progression, making it a potential tumor-related marker. Recent studies have shed light on the critical roles of DCLK1 and tuft cells in the immune response and the maintenance of epithelial homeostasis, as well as targeted immune escape mechanisms in the tumor microenvironment. This review aims to comprehensively examine the current understanding of immune-related functions mediated by DCLK1 and tuft cells in epithelial tissues, including the roles of relevant cells and important factors involved. Additionally, this review will discuss recent advances in anti-tumor immunity mediated by DCLK1/tuft cells and their potential as immunotherapeutic targets. Furthermore, we will consider the potential impact of DCLK1 targeted therapy in cancer immunotherapy, particularly DCLK1 kinase inhibitors as potential therapeutic drugs in anti-tumor immunity, providing a new perspective and reference for future research.
双皮质素样激酶1（DCLK1）是一种簇状细胞标志物，在各种肿瘤中广泛表达。其高表达水平与恶性肿瘤进展密切相关，使其成为一种潜在的肿瘤相关标志物。最近的研究揭示了DCLK1和簇状细胞在免疫反应、上皮内稳态维持以及肿瘤微环境中的靶向免疫逃逸机制中的关键作用。本综述旨在全面审视目前对上皮组织中由DCLK1和簇状细胞介导的免疫相关功能的理解，包括相关细胞的作用和涉及的重要因素。此外，本综述将讨论由DCLK1/簇状细胞介导的抗肿瘤免疫的最新进展及其作为免疫治疗靶点的潜力。此外，我们将考虑DCLK1靶向治疗在癌症免疫治疗中的潜在影响，特别是DCLK1激酶抑制剂作为抗肿瘤免疫中的潜在治疗药物，为未来研究提供新的视角和参考。
